XNASIMMX
Market cap57mUSD
Dec 26, Last price
2.10USD
1D
-3.67%
1Q
34.62%
IPO
-47.50%
Name
Immix Biopharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
P
Net income
-15m
L+87.44%
CFO
-11m
L+53.50%
Earnings
Mar 27, 2025
Profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | (89,517) | ||||
Cost of revenue | 16,147 | 8,221 | 1,354 | ||
Unusual Expense (Income) | |||||
NOPBT | (16,147) | (97,738) | (1,354) | ||
NOPBT Margin | 109.18% | ||||
Operating Taxes | 26 | 10 | 6 | ||
Tax Rate | |||||
NOPAT | (16,173) | (97,748) | (1,360) | ||
Net income | (15,426) 87.44% | (8,230) -66.25% | (24,384) 2,024.28% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 15,696 | 2,814 | 18,649 | ||
BB yield | -13.08% | -9.29% | -39.60% | ||
| Debt | |||||
Debt current | 50 | ||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 475 | ||||
Net debt | (17,510) | (13,437) | (17,594) | ||
| Cash flow | |||||
Cash from operating activities | (11,371) | (7,408) | (1,589) | ||
CAPEX | (52) | (802) | |||
Cash from investing activities | (52) | (802) | |||
Cash from financing activities | 15,464 | 3,232 | 18,849 | ||
FCF | (16,032) | (97,544) | (2,387) | ||
| Balance | |||||
Cash | 17,510 | 13,437 | 17,644 | ||
Long term investments | |||||
Excess cash | 17,510 | 17,913 | 17,644 | ||
Stockholders' equity | (53,476) | (37,897) | (29,629) | ||
Invested Capital | 69,680 | 51,532 | 47,669 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 17,341 | 13,229 | 13,229 | ||
Price | 6.92 202.18% | 2.29 -35.67% | 3.56 | ||
Market cap | 120,001 296.12% | 30,294 -35.67% | 47,094 | ||
EV | 102,289 | 16,857 | 29,500 | ||
EBITDA | (16,141) | (97,736) | (1,352) | ||
EV/EBITDA | |||||
Interest | 497 | 180 | |||
Interest/NOPBT | |||||